S-100A10 Activators
The chemical class known as S100A10 Activators comprises a diverse group of molecules and compounds that demonstrate the capacity to enhance the activity or function of the S100A10 protein, also known as p11. S100A10 is a member of the S100 protein family and participates in various cellular processes, including calcium-mediated signaling, membrane trafficking, and protein interactions. Activation of S100A10 by these activators is thought to potentially amplify its role in specific cellular functions. The mechanisms through which S100A10 activators exert their effects could involve interactions with partner proteins, such as annexin A2, resulting in the formation of complexes that influence membrane interactions or vesicular transport.
Thapsigargin, operates as a potent inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump. By blocking SERCA, Thapsigargin disrupts calcium homeostasis, leading to increased intracellular calcium levels. Elevated calcium levels can activate signaling pathways involving S-100A10, suggesting a potential avenue for its indirect activation through altered calcium dynamics. A23187, a calcium ionophore, facilitates the transport of calcium across cellular membranes, promoting intracellular calcium influx. This property positions A23187 as a chemical tool to investigate the impact of altered calcium dynamics on S-100A10 activity. The ionophore serves as a means to indirectly activate S-100A10 through the manipulation of cellular calcium signaling. Calmidazolium, a calmodulin antagonist, disrupts calcium-calmodulin interactions, potentially influencing S-100A10 through the modulation of calmodulin-dependent processes. This indirect activation pathway provides insight into how calmodulin-mediated cellular events can impact S-100A10 activity. These chemicals, along with others in the S-100A10 activator class, showcase a diversity of mechanisms by which they can indirectly influence S-100A10. Whether through alterations in calcium dynamics, interference with calmodulin-dependent processes, or modulation of specific signaling pathways, these activators provide valuable tools for studying the intricate regulation of S-100A10 in cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a potent inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump. By blocking SERCA, thapsigargin disrupts calcium homeostasis, leading to increased intracellular calcium levels. Elevated calcium levels can activate signaling pathways involving S-100A10, making thapsigargin a potential indirect activator of S-100A10 through modulation of cellular calcium signaling. | ||||||
Calmodulin (human), (recombinant) | 73298-54-1 | sc-471287 | 1 mg | $300.00 | ||
Calmodulin, a calcium-binding protein, might interact with S100A10 to modulate its activity, as both proteins are involved in calcium signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187, also known as calcimycin, is a calcium ionophore that facilitates the transport of calcium across cellular membranes. By promoting intracellular calcium influx, A23187 can activate signaling cascades involving S-100A10. This ionophore serves as a chemical tool to investigate the impact of altered calcium dynamics on S-100A10 activity, potentially leading to its activation in a calcium-dependent manner. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $156.00 $612.00 | 27 | |
Calmidazolium is a calmodulin antagonist that interferes with calcium-calmodulin interactions. By disrupting the calmodulin-dependent regulation of various proteins, including those involved in calcium signaling pathways, calmidazolium can indirectly modulate S-100A10 activity. Its impact on calmodulin-mediated cellular processes may contribute to the activation of S-100A10 through altered calcium-dependent signaling pathways. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
ML-9 is a myosin light chain kinase (MLCK) inhibitor that affects cellular processes related to actomyosin dynamics. Since S-100A10 is implicated in modulating the actin cytoskeleton, ML-9 may indirectly activate S-100A10 by influencing actomyosin-driven cellular processes. The inhibition of MLCK by ML-9 can lead to alterations in the actin cytoskeleton, potentially impacting the regulatory functions of S-100A10 in this context. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is a selective protein kinase C (PKC) inhibitor that can impact cellular signaling pathways involving S-100A10. By inhibiting PKC, Gö6976 may indirectly activate S-100A10 through modulation of downstream PKC-dependent events. The altered activity of PKC can influence S-100A10-associated functions, possibly leading to its activation in response to changes in PKC-mediated signaling cascades. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinase (PI3K), affecting cellular processes related to phosphoinositide signaling. Since S-100A10 is implicated in PI3K-mediated pathways, wortmannin may indirectly activate S-100A10 by disrupting PI3K-dependent events. The inhibition of PI3K by wortmannin can lead to alterations in the downstream signaling cascades involving S-100A10, potentially influencing its activity in response to changes in PI3K-mediated signaling. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a general protein kinase C (PKC) inhibitor that can influence cellular signaling pathways involving S-100A10. By inhibiting PKC, bisindolylmaleimide I may indirectly activate S-100A10 through modulation of downstream PKC-dependent events. The altered activity of PKC can impact S-100A10-associated functions, possibly leading to its activation in response to changes in PKC-mediated signaling cascades. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG 1478 is a selective inhibitor of epidermal growth factor receptor (EGFR), impacting cellular processes related to EGFR signaling. Since S-100A10 is implicated in pathways influenced by EGFR, AG 1478 may indirectly activate S-100A10 by disrupting EGFR-dependent events. The inhibition of EGFR by AG 1478 can lead to alterations in downstream signaling cascades involving S-100A10, potentially influencing its regulatory functions in response to changes in EGFR-mediated signaling. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a selective c-Raf inhibitor that affects the mitogen-activated protein kinase (MAPK) pathway. Given S-100A10's involvement in cellular processes influenced by MAPK signaling, GW5074 may indirectly activate S-100A10 by disrupting MAPK-dependent events. The inhibition of c-Raf by GW5074 can lead to alterations in the MAPK pathway, potentially influencing the regulatory functions of S-100A10 in response to changes in MAPK-mediated signaling cascades. | ||||||